EU Authorized Representative for Medical Devices and IVDs in Europe
For manufacturers based outside the European Union, bringing medical devices or in vitro diagnostic devices into the European market involves more than product quality, technical documentation and regulatory preparation. Before any device is introduced to the European market, the manufacturer must appoint an EU Authorized Representative based within the European Union and formally recognised as the manufacturer’s authorised representative. This function is critical under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation as regulators require a responsible local entity to manage communication, supply documentation and assist with compliance obligations when needed. An eu-authorized-representative is not simply a name on a label. They serve as the legal presence of a non-EU manufacturer and play a vital role in ensuring market access, regulatory trust and ongoing post-market accountability.
Why an EU Authorized Representative Is Required
European medical device rules are designed to protect patients, healthcare professionals and users by ensuring that every product placed on the market has a clear chain of responsibility. When a manufacturer is based outside the European Union, regulators cannot always deal with that manufacturer directly in the same practical way they would with a local company. This is where the EU Authorized Representative becomes necessary. The representative provides a formal local presence and serves as the official point of communication for Competent Authorities, Notified Bodies and other regulatory stakeholders.
Without designating an authorised representative, a non-EU manufacturer is not permitted to place medical devices or IVDs on the European market. This requirement applies across a broad spectrum of products, from low-risk devices to advanced diagnostic technologies. This obligation applies before market entry, meaning the representative must be selected early in the compliance journey rather than as a last administrative step. For companies preparing for European distribution, selecting the right EU Authorized Representative for Medical Devices and IVDs can significantly influence registration readiness, document management and long-term regulatory stability.
The Written Mandate Between Manufacturer and Representative
The connection between the manufacturer and the EU Authorized Representative must be formalised through a written mandate. This mandate defines the tasks the representative is authorised to perform and confirms the obligations both parties must follow. It is a critical compliance record as it defines the scope of representation, responsibilities, communication roles and the actions required if compliance issues occur.
A vague or poorly prepared mandate can create uncertainty at the worst possible time, especially during an authority request, inspection, complaint review or corrective action. A strong mandate should clearly describe how documents will be made available, how regulatory communication will be handled, how incident information will be shared and what happens if the manufacturer does not meet its duties. For this reason, the mandate should be prepared carefully and reviewed before device registration or market placement begins.
Label and Packaging Requirements
The name and address of the EU Authorized Representative must be displayed on the device label, packaging or associated product information in accordance with applicable regulations. This allows authorities, distributors, healthcare professionals and users to identify the local representative linked to the device. It also reinforces the representative’s role as the official European presence for a manufacturer located outside the European Union.
Labelling accuracy matters because incorrect or missing representative information can create compliance concerns and may delay market access. Manufacturers should ensure that their artwork, instructions, declarations and registration information are aligned before products are released. If the representative changes, labelling and registration details may also need to be updated in a controlled and timely manner.
Documentation Review and Availability
One of the important duties of an EU Authorized Representative for Medical Devices and IVDs is to verify that key compliance documents are available and properly prepared. This includes checking that the EU Declaration of Conformity exists, that technical documentation has been compiled and that the manufacturer has followed an appropriate conformity assessment route for the device type and risk class.
The representative may also be required to retain or access copies of technical files, declarations and Notified Body certificates. These records must remain accessible for inspection by Competent Authorities for the specified retention period after the last device is marketed. This places document control at the core of the manufacturer–representative relationship. Manufacturers should maintain updated records and ensure that the representative can respond quickly if regulators request information.
Communication With Competent Authorities and Notified Bodies
The EU Authorized Representative acts as the official communication channel between the non-EU manufacturer and European regulatory authorities. If a Competent Authority requests information, samples, technical documentation or clarification, the representative is expected to support the response eu-authorized-representative process. The representative may also liaise with Notified Bodies when necessary, particularly regarding certification, conformity assessments or corrective measures.
This communication function goes beyond simply passing messages. A dependable representative should understand regulatory requirements, maintain accurate records and ensure responses are delivered within required timelines. Late or incomplete replies can lead to serious consequences, including market limitations or additional regulatory scrutiny. Therefore, manufacturers should partner with a representative who has strong regulatory expertise and well-defined internal systems.
Post-Market Surveillance and Incident Support
Compliance for medical devices does not stop once the product reaches the market. After a device is in circulation, manufacturers must continuously monitor performance, complaints, incidents and safety indicators. The EU Authorized Representative supports this post-market obligation by promptly forwarding complaints and incident reports to the manufacturer.
This is particularly critical when information originates from clinicians, patients, users, distributors or authorities. Timely communication helps the manufacturer assess whether further investigation, reporting, field safety action or corrective action is needed. An effective representative recognises that post-market surveillance goes beyond documentation. It plays a key role in patient safety, product enhancement and continued regulatory confidence.
Registration Responsibilities and EUDAMED
Under European regulatory systems, manufacturer and representative details must be registered as required. The EU Authorized Representative may assist with registering both manufacturer and representative data in EUDAMED. Accurate registration helps authorities identify responsible parties, review device information and maintain market oversight.
Manufacturers should gather complete company information, device details, certificates and declarations before starting registration. Any mismatch between labelling, declarations, technical documentation and registration records may lead to delays or compliance concerns. The representative’s involvement helps ensure that required information is properly aligned and available when needed.
When the Representative Must Take Action
An EU Authorized Representative also carries responsibilities if the manufacturer does not fulfil regulatory requirements. If significant non-compliance arises and is not corrected by the manufacturer, the representative may need to terminate the mandate and notify relevant authorities and the Notified Body where relevant. This responsibility highlights that the role extends beyond administrative tasks.
The representative holds legal responsibility and cannot overlook serious compliance breaches. Manufacturers should therefore view the representative as a regulatory partner rather than a passive provider. Clear communication, regular document updates and defined responsibilities help avoid misunderstandings and minimise risk throughout the product lifecycle.
Choosing the Right EU Authorized Representative
Choosing an EU Authorized Representative requires careful consideration. Manufacturers should evaluate regulatory expertise, experience in medical devices and IVDs, document management capabilities, clear response processes and strong knowledge of European regulations. The representative should be able to support communication with authorities, maintain records and guide the manufacturer on practical compliance expectations.
Cost alone should not determine the choice. An ineffective representative may lead to delays, communication gaps and increased risk, whereas a strong representative can support confidence during market entry and beyond. The right choice gives non-EU manufacturers a dependable European presence and supports smoother regulatory management.
Conclusion
An EU Authorized Representative is a mandatory requirement for non-EU manufacturers aiming to introduce medical devices or IVDs into the European market. The role covers legal representation, document availability, regulatory communication, complaint management, registration assistance and intervention in cases of serious non-compliance. Under the Medical Device Regulation and In Vitro Diagnostic Medical Device Regulation, appointing an authorised representative is not optional and should be completed before market placement begins. By choosing a competent EU Authorized Representative for Medical Devices and IVDs, manufacturers can strengthen compliance, support patient safety and build a reliable foundation for long-term access to the European market.